Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jessica Weber

Vascular & Interventional Radiology Tulsa, OK Doctor of Osteopathy

NPI 1528397106 CMS profile 160510

5801 E 41St St Ste 900, Tulsa, OK 74135

Open in the dashboard

General payments

$4,575

73 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Weber of Tulsa, OK is reported in the CMS Open Payments database as having received $4,575 across 73 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $857 16
2024 General $673 8
2023 General $409 8
2022 General $376 6
2021 General $488 8
2020 General $501 7
2019 General $1,270 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Weber
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Jessica Weber were reported at $857. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Jessica Weber Vascular & Interventional Radiology median Middle half National median
2019 $1,270 $422 $125–$1,555 $163
2020 $501 $200 $68–$652 $114
2021 $488 $280 $99–$866 $132
2022 $376 $433 $137–$1,497 $149
2023 $409 $506 $152–$2,019 $160
2024 $673 $556 $175–$1,930 $164
2025 $857 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $800 8 payments
  2. Bard Peripheral Vascular, Inc. $714 9 payments
  3. Surefire Medical, Inc. $679 12 payments
  4. Sirtex Medical Inc $587 11 payments
  5. Medtronic, Inc. $581 6 payments
  6. Terumo Medical Corporation $406 7 payments
  7. Boston Scientific Corporation $281 7 payments
  8. Endocare, Inc. $156 2 payments
  9. Intuitive Surgical, Inc. $130 1 payment
  10. Imperative Care, INc $63 2 payments
  11. Other $178 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,462 71 payments
  2. Education $90 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24 1 payment
Products named General payments · program years 2019–2025
  1. TRINAV INFUSION SYSTEM $679 12 payments
  2. SIR-Spheres Microspheres $587 11 payments
  3. Indigo System $422 3 payments
  4. Glidesheath $323 3 payments
  5. IN.PACT AV $269 3 payments
  6. TR Band $218 4 payments
  7. RUBY Coil $208 2 payments
  8. Abre $197 2 payments
  9. RED 72 $163 2 payments
  10. VENOVO $134 1 payment
  11. Other $1,190 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 125 billing codes

Paid by Medicare

$108,950

Of which drugs: $68

Medicare patients

354

Average age 72

Services billed

1,296

192 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Chronic kidney disease 45%
Diabetes 40%
Heart failure 34%
Cancer 34%
Depression 32%
Ischemic heart disease 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, cefazolin sodium, 500 mg J0690 Office 20 78 $47

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

73 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record